Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients

Saleeb, Mina Fayez; Sabry, Sabry Magdy; Mahmoud, Mohammad Salah; Nassif, Mena Maher

doi:10.1186/s43163-023-00406-2

The Egyptian Journal of Otolaryngology

Table 6 Duration between COVID-19 infection and start of mucormycosis

From: Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients

	Duration between COVID-19 infection and start of mucormycosis (days)		Test value	p-value	Sig.
	Median (IQR)	Range	Test value	p-value	Sig.
Sex
Male	30 (21–60)	14–90	−0.298^a	0.765	NS
Female	30 (20–45)	7–90	−0.298^a	0.765	NS
Occupation
Not working	30 (25–40)	21– 0	1.124^b	0.891	NS
Housewife	30 (20–45)	7–90
Employer	21 (14–90)	14–90
Worker	37 (14–60)	14–60
On pension	60 (60–60)	60–60
Smoking
No	30 (20–60)	7–90	−0.213^a	0.832	NS
Yes	25 (21–60)	14–80	−0.213^a	0.832	NS
Diabetes
No	25.5 (21–30)	21–30	−0.517^a	0.605	NS
Yes	30 (20.5–60)	7–90	−0.517^a	0.605	NS
Controlled
No	40 (14–60)	7–80	−0.305^a	0.760	NS
Yes	30 (21–60)	14–90	−0.305^a	0.760	NS
Newly diagnosed
No	30 (21–60)	7–90	−0.958^a	0.338	NS
Yes	20 (20–20)	20–20	−0.958^a	0.338	NS
DKA on admission
No	40 (25–75)	14–90	−2.367^a	0.018	S
Yes	14 (14–20)	7–45	−2.367^a	0.018	S
Prolonged antibiotic or antiviral therapy
No	42.5 (30–60)	14–90	−2.540^a	0.011	S
Yes	20.5 (14–23)	7–80	−2.540^a	0.011	S
Prolonged steroid use
No	30 (21–60)	7–90	−0.714^a	0.476	NS
Yes	21 (21–21)	21–21	−0.714^a	0.476	NS
Fever
No	30 (21–67.5)	7–90	−1.001^a	0.317	NS
Yes	25 (14–45)	14–60	−1.001^a	0.317	NS
Facial numbness
No	27.5 (21–30)	14–90	−0.398^a	0.691	NS
Yes	42.5 (17–60)	7–90	−0.398^a	0.691	NS
Facial swelling
No	37.5 (27.5–67.5)	21–90	−2.023^a	0.043	S
Yes	20.5 (14–40)	7–90	−2.023^a	0.043	S
Headache
No	30 (25–80)	21–90	−0.993^a	0.321	NS
Yes	30 (14–60)	7–90	−0.993^a	0.321	NS
Facial pain
No	30 (25–80)	21–90	−0.853^a	0.394	NS
Yes	30 (17–52.5)	7–90	−0.853^a	0.394	NS
Rhinorrhea, blood stained
No	21 (14–75)	7–90	−1.418^a	0.156	NS
Yes	45 (30–60)	25–60	−1.418^a	0.156	NS
Orbital swelling
No	50 (25.5–85)	14–90	−1.648^a	0.099	NS
Yes	27.5 (20–45)	7–75	−1.648^a	0.099	NS
Ophthalmoplegia
No	30 (21–60)	7–90	−0.429^a	0.668	NS
Yes	30 (20–60)	14–80	−0.429^a	0.668	NS

P-value > 0.05, nonsignificant; P-value < 0.05, significant; P-value < 0.01, highly significant
The previous table shows that there was significant decrease in duration (days) with incidence of DKA on admission with median (IQR) = (14 (14–23) vs 40 (25–75)) and P-value = 0.018
^aMann-Whitney test
^bKruskal-Wallis test

Back to article page